8-K: Intelligent Bio Solutions Reports Record Q1 Revenue Growth

Intelligent Bio Solutions Inc. announced record first-quarter fiscal 2026 revenue of $1.11 million, driven by strong cartridge sales and strategic market expansion, despite an increased net loss.

Summary

• Record quarterly revenue of $1.11 million for fiscal Q1 2026, a 32% sequential increase and 28% year-over-year.
• Gross profit margins rose to 46.6%, an increase of 690 basis points year-over-year, primarily due to higher margin cartridge sales.
• Cartridge sales accounted for $640,300, or 57.59% of total revenue, up from 51.1% in the prior year's first quarter.
• Added 33 new customer accounts, bringing the total to 492 across more than 24 countries.
• Net loss for the quarter was $(2,994,992), an increase from $(2,694,799) in the same period last year.
• Net loss per share improved to $(0.35) from $(0.70) year-over-year, despite a higher total net loss, due to a significant increase in weighted average shares outstanding (8,546,934 vs 3,811,090).
• Operating expenses increased to $(3,711,151) from $(3,198,190) year-over-year, primarily due to higher selling, general and administrative expenses and an impairment of long-lived assets.

Sentiment

Score: 5

Explanation: While revenue growth and gross margin expansion are strong positives, the significant increase in net loss, operating expenses, and shareholder dilution temper the overall sentiment. The company is growing but at a high cost, indicating ongoing challenges in achieving profitability despite operational improvements.

Positives

• Record quarterly revenue of $1.11 million, representing 32% sequential growth and 28% year-over-year growth.
• Significant improvement in gross profit margins, increasing by 690 basis points year-over-year to 46.6%.
• Strong performance in consumable cartridge sales, which now represent nearly 58% of total revenue, indicating a robust recurring revenue model.
• Successful customer acquisition, adding 33 new accounts and expanding the active customer base to 492 across 24+ countries.
• Secured a major contract with a London public transport operator, covering 14 operational sites and over 4,400 staff.
• Expanded product portfolio with the SmarTest Patch, an innovative 7-10 day continuous drug monitoring solution.
• Established a global distribution agreement with SMARTOX for the SmarTest Patch, enhancing international market reach.
• Net loss per share improved to $(0.35) from $(0.70) year-over-year, despite an increased net loss, due to a larger share base.

Negatives

• Net loss increased to $(2,994,992) for the quarter, compared to $(2,694,799) in the prior year period.
• Loss from operations increased to $(2,999,593) from $(2,725,261) year-over-year.
• Selling, general and administrative expenses significantly increased to $(2,659,824) from $(1,949,016) year-over-year.
• Incurred an impairment of long-lived assets of $(261,780) during the quarter, which was not present in the prior year.
• Weighted average shares outstanding more than doubled year-over-year (8,546,934 vs 3,811,090), indicating significant dilution.

Risks

• Ability to successfully develop and commercialize drug and diagnostic tests.
• Ability to realize commercial benefit from partnerships and collaborations.
• Ability to secure necessary regulatory approvals, such as planned FDA clearance.
• Uncertainty of future events or outcomes.
• Known and unknown risks, uncertainties, and other factors included in public SEC filings.

Future Outlook

The company anticipates sustained growth driven by its focus on consumable cartridge sales and expects to advance along the regulatory pathway toward planned FDA clearance and U.S. market entry. It also projects continued revenue diversification and market growth throughout fiscal 2026, leveraging new product additions and international partnerships.

Management Comments

• "Our first quarter results show accelerating momentum of our business model and the growing market adoption internationally of our non-invasive drug screening technology." Harry Simeonidis, President and CEO.
• "We achieved record quarterly revenue of $1.11 million, representing our strongest quarter to date, with 32% growth sequentially and 28% year-over-year." Harry Simeonidis, President and CEO.
• "This significant revenue increase, combined with expanding gross margins, validates our strategic focus on consumable cartridge sales and positions us well for sustained growth as we advance along the regulatory pathway toward planned FDA clearance and U.S. market entry." Harry Simeonidis, President and CEO.
• "As our first fiscal quarter results show, the financial discipline implemented throughout fiscal 2025 is now translating into meaningful margin expansion and operational leverage." Spiro Sakiris, CFO.
• "We are seeing strong returns on strategic investments, with improved customer acquisition metrics and accelerating revenue per account." Spiro Sakiris, CFO.
• "We believe that we are well positioned to capitalize on the growth opportunities ahead." Spiro Sakiris, CFO.

Industry Context

The announcement highlights Intelligent Bio Solutions' position in the growing market for non-invasive, rapid drug screening solutions, a trend driven by increasing demand for privacy, dignity, and operational efficiency in workplace testing. The expansion into continuous drug monitoring with the SmarTest Patch and international distribution agreements align with broader industry movements towards diversified testing methods and global market penetration for medical technology companies.

Stakeholder Impact

• Shareholders: Experience significant dilution from increased share count, but also benefit from revenue growth and strategic expansion. The increased net loss could be a concern for profitability.
• Customers: Benefit from expanded product offerings (SmarTest Patch) and broader availability through international partnerships.
• Employees: The company's growth and strategic initiatives may lead to increased opportunities.
• Creditors: The ongoing net losses and need for capital could be a consideration, though the balance sheet shows an increase in cash.

Next Steps

• Advance along the regulatory pathway toward planned FDA clearance for U.S. market entry.
• Continue international expansion and secure large-scale deployments.
• Drive revenue diversification and market growth throughout fiscal 2026.
• Capitalize on growth opportunities ahead.

Key Dates

Recommendation

The company demonstrates strong top-line growth and impressive gross margin expansion, driven by a successful consumable-focused business model and strategic international expansion. The addition of new products and partnerships also bodes well for future revenue diversification. However, these positives are significantly offset by a substantial increase in net loss, higher operating expenses (particularly SG&A), and considerable shareholder dilution. While the per-share loss improved, the underlying total loss widened. Investors should 'hold' to monitor if the company can translate its revenue growth and operational efficiencies into improved profitability and reduced cash burn, especially as it pursues FDA clearance and U.S. market entry, which will likely require further investment.

Keywords

Intelligent Bio Solutions, INBS, Drug Screening, Medical Technology, Fingerprint Technology, Non-invasive Testing, Consumable Cartridges, FDA Clearance, SmarTest Patch, Financial Results, Q1 2026, Revenue Growth, Gross Margin, Biotechnology